CARBAPENEM-BASED ANTIBIOTICS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-60342 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Carbapenem-based Antibiotics Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL CARBAPENEM-BASED ANTIBIOTICS MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL CARBAPENEM-BASED ANTIBIOTICS MARKET

7.1 GLOBAL CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA CARBAPENEM-BASED ANTIBIOTICS MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 ACS Dobfar S.p.A.

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Amneal Pharmaceuticals LLC

16.3 Apotex, Inc.

16.4 Aurobindo Pharma Ltd.

16.5 Daewoong Pharmaceutical Co., Ltd.

16.6 Fedora Pharmaceuticals, Inc.

16.7 Gland Pharma Ltd. (Fosun Pharmaceutical Co., Ltd.)

16.8 Iterum Therapeutics plc

16.9 Jeil Pharmaceutical Co., Ltd.

16.10 Johnson & Johnson Pharmaceuticals

16.11 Meiji Seika Pharma Co., Ltd.

16.12 Merck & Co., Inc.

16.13 Pfizer, Inc.

16.14 Savior Lifetec Corporation

16.15 Spero Therapeutics, Inc.

16.16 Sumitomo Dainippon Pharma Co., Ltd.

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Product Type
Meropenem
Ertapenem
Imipenem
Doripenem
Panipenem
Tebipenem

By Indication
Intra-abdominal Infections
Urinary Tract Infections
Pneumonia
Bacterial Meningitis
Skin and Skin Structure Infections
Acute Pelvic Infections
Prophylaxis of Surgical Site Infection
Respiratory Tract Infections
Gynaecologic Infections
Endocarditis
Others

By Distribution Channel
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Online Pharmacies

Companies

ACS Dobfar S.p.A.
Amneal Pharmaceuticals LLC
Apotex, Inc.
Aurobindo Pharma Ltd.
Daewoong Pharmaceutical Co., Ltd.
Fedora Pharmaceuticals, Inc.
Gland Pharma Ltd. (Fosun Pharmaceutical Co., Ltd.)
Iterum Therapeutics plc
Jeil Pharmaceutical Co., Ltd.
Johnson & Johnson Pharmaceuticals
Meiji Seika Pharma Co., Ltd.
Merck & Co., Inc.
Pfizer, Inc.
Savior Lifetec Corporation
Spero Therapeutics, Inc.
Sumitomo Dainippon Pharma Co., Ltd.

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.